Orexigen Therapeutics (OREX) 5.74 $OREX
Contrave Sales Continue To Impress
Spencer Osborne - at Seeking Alpha - Fri Dec 12, 3:26PM CST
OREX: 5.74 (-0.02), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Arena: Belviq Sales See Pleasant Rebound
Spencer Osborne - at Seeking Alpha - Fri Dec 12, 3:05PM CST
OREX: 5.74 (-0.02), ARNA: 3.91 (-0.18)
Assessing The Beginnings Of The Orexigen Launch Of Contrave
Spencer Osborne - at Seeking Alpha - Wed Dec 10, 12:09PM CST
OREX: 5.74 (-0.02), ARNA: 3.91 (-0.18)
38.0% Return Seen to Date on SmarTrend Orexigen Therapeutics Call (OREX)
Comtex SmarTrend(R) - Wed Dec 10, 11:00AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on October 17th, 2014 at $4.16. In approximately 2 months, Orexigen Therapeutics has returned 37.98% as of today's recent price of $5.74.
OREX: 5.74 (-0.02)
Contrave Sales Are Driven By Reps And Discounts, Not Insurance (Yet)
Clinically Sound Investor - at Seeking Alpha - Tue Dec 09, 12:12PM CST
OREX: 5.74 (-0.02)
Global Anti-Obesity Drugs Market 2015-2019: High Drug Development Costs & Stiff Market Competition
M2 - Mon Dec 08, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/pvmmtv/global) has announced the addition of the "Global Anti-Obesity Drugs Market 2015-2019" report to their offering. The Global Anti-obesity Drugs market to grow at a CAGR of 39.45 percent over the period 2014-2019 Obesity is a medical condition in which there is surplus accumulation of fat in the body. It is linked with increased illness risk, disability, and death. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure. Fierce competition among vendors to manufacture and market drugs that are both effective and safe is one of the major trends in the market. Competition in the market is expected to further intensify with the entry of new drugs in the market during the forecast period. The landscape is vast, with competitors ranging from Arena Pharmaceuticals and Orexigen Therapeutics to big pharmaceutical companies gearing up to make harmless anti-obesity drugs with lesser side effects. According to the report, an increase in the prevalence of obesity is one of the main drivers of the market. The prevalence of obesity is very high worldwide. An increase in the prevalence of obesity offers huge opportunities for drug manufacturing companies to develop and manufacture highly effective drugs. Further, the report states that the high cost of development of drugs is one of the primary challenges faced by the market. Regardless of the numerous benefits, the high cost involved with the development of anti-obesity drugs has direct impact on the pricing of the drug, thereby impeding the acceptability among patients. The Global Anti-obesity Drugs market can be divided into two segments: - Peripherally Acting Anti-obesity Drugs - Centrally Acting Anti-obesity Drugs Key Vendors - Arena Pharmaceuticals - F. Hoffmann-La Roche - GlaxoSmithKline - Orexigen Therapeutics - Vivus Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Types of Obesity - Causes of Obesity - Classification of Obesity - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/pvmmtv/global
OREX: 5.74 (-0.02), GSK: 42.42 (-0.93), ARNA: 3.91 (-0.18)
This Growing Concern Accounts For Nearly 500,000 Cancer Cases Each Year
Sean Williams, The Motley Fool - Motley Fool - Sun Dec 07, 12:51PM CST
Source: WIkimedia Commons. When it comes to diagnosed diseases and disorders few, if any, are scarier than cancer. Based on statistics from the Centers for Disease Control and Prevention, cancer is the second-leading cause of death in the United...
ZFGN: 22.56 (+0.08), OREX: 5.74 (-0.02), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Will Diabetes Drugs Enter The Anti-Obesity Space?
Spencer Osborne - at Seeking Alpha - Sun Dec 07, 5:58AM CST
OREX: 5.74 (-0.02), NVO: 44.48 (-1.14), AZN: 71.80 (-1.80), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Critical Alerts For Apache Corporation, Dreamworks Animation, FireEye, CyberArk Software and Orexigen Therapeutics Released By InvestorsObserver
PR Newswire - Fri Dec 05, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for APA, DWA, FEYE, CYBR and OREX.
OREX: 5.74 (-0.02), FEYE: 29.12 (-0.32), CYBR: 37.98 (+0.13), APA: 56.44 (-0.60), DWA: 21.75 (+0.04)
Why Orexigen Therapeutics (OREX) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 7:52AM CST
Orexigen Therapeutics is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
OREX: 5.74 (-0.02)
Orexigen Therapeutics Up 43.5% Since SmarTrend Uptrend Call (OREX)
Comtex SmarTrend(R) - Wed Dec 03, 9:38AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on October 17th, 2014 at $4.16. In approximately 2 months, Orexigen Therapeutics has returned 43.51% as of today's recent price of $5.97.
OREX: 5.74 (-0.02)
Earnings Estimates Moving Higher for Orexigen (OREX): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 7:51AM CST
Orexigen has been witnessing an upward trend in its current year earnings estimate and its share price has been rising for past 4 weeks
OREX: 5.74 (-0.02)
Why Orexigen Therapeutics, Inc. Stock Rocketed 43% Higher in November
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 03, 7:36AM CST
OREX data by YCharts What: Shares of Orexigen Therapeutics , a biopharmaceutical company focused on developing drugs to treat obesity, put on some serious heft and gained 43% during the month of November, data courtesy of S&P Capital IQ...
OREX: 5.74 (-0.02), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Strong On High Volume: Orexigen Therapeutics (OREX)
at The Street - Tue Dec 02, 9:01AM CST
Trade-Ideas LLC identified Orexigen Therapeutics (OREX) as a strong on high relative volume candidate
OREX: 5.74 (-0.02)
Orexigen Therapeutics Has Returned 39.2% Since SmarTrend Recommendation (OREX)
Comtex SmarTrend(R) - Wed Nov 26, 9:11AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on October 17th, 2014 at $4.16. In approximately 1 month, Orexigen Therapeutics has returned 39.18% as of today's recent price of $5.79.
OREX: 5.74 (-0.02)
Orexigen Therapeutics to Present at the Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 26, 7:30AM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Piper Jaffray Healthcare Conference in New York. The presentation is scheduled for Wednesday, December 3rd at 12:30 p.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
OREX: 5.74 (-0.02)
December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey
at The Street - Wed Nov 26, 5:00AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.
BLUE: 91.28 (+5.16), OREX: 5.74 (-0.02), BCRX: 10.06 (+0.02), ALNY: 100.45 (+0.23), ACHN: 13.28 (-0.11), MRK: 57.72 (-1.62), INCY: 74.65 (-1.27), EPZM: 18.35 (-1.45), AGIO: 119.56 (+0.36), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)
Arena Pharmaceuticals: Belviq Sales Take A Modest Dip With Holiday
Spencer Osborne - at Seeking Alpha - Sat Nov 22, 1:51PM CST
OREX: 5.74 (-0.02), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl extended release)
PR Newswire - Fri Nov 21, 7:00AM CST
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the Company has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for U.S. Patent Application No. 11/757,773, which covers use of Orexigen's sustained release formulation of naltrexone, which was designed to improve drug tolerability for Contrave® (naltrexone HCl / bupropion HCl extended release), in a method for treating obesity. The patent is expected to expire in March of 2028. Orexigen expects the patent to be listed in the Orange Book maintained by the United States Food and Drug Administration.
OREX: 5.74 (-0.02)
Uptrend Call Working As Orexigen Therapeutics Stock Rises 35.1% (OREX)
Comtex SmarTrend(R) - Tue Nov 18, 4:54PM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on October 17th, 2014 at $4.16. In approximately 1 month, Orexigen Therapeutics has returned 35.10% as of today's recent price of $5.62.
OREX: 5.74 (-0.02)
Contrave Sales Continue To Impress
Spencer Osborne - at Seeking Alpha - Fri Dec 12, 3:26PM CST
OREX: 5.74 (-0.02), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Arena: Belviq Sales See Pleasant Rebound
Spencer Osborne - at Seeking Alpha - Fri Dec 12, 3:05PM CST
OREX: 5.74 (-0.02), ARNA: 3.91 (-0.18)
Assessing The Beginnings Of The Orexigen Launch Of Contrave
Spencer Osborne - at Seeking Alpha - Wed Dec 10, 12:09PM CST
OREX: 5.74 (-0.02), ARNA: 3.91 (-0.18)
38.0% Return Seen to Date on SmarTrend Orexigen Therapeutics Call (OREX)
Comtex SmarTrend(R) - Wed Dec 10, 11:00AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on October 17th, 2014 at $4.16. In approximately 2 months, Orexigen Therapeutics has returned 37.98% as of today's recent price of $5.74.
OREX: 5.74 (-0.02)
Contrave Sales Are Driven By Reps And Discounts, Not Insurance (Yet)
Clinically Sound Investor - at Seeking Alpha - Tue Dec 09, 12:12PM CST
OREX: 5.74 (-0.02)
Global Anti-Obesity Drugs Market 2015-2019: High Drug Development Costs & Stiff Market Competition
M2 - Mon Dec 08, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/pvmmtv/global) has announced the addition of the "Global Anti-Obesity Drugs Market 2015-2019" report to their offering. The Global Anti-obesity Drugs market to grow at a CAGR of 39.45 percent over the period 2014-2019 Obesity is a medical condition in which there is surplus accumulation of fat in the body. It is linked with increased illness risk, disability, and death. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure. Fierce competition among vendors to manufacture and market drugs that are both effective and safe is one of the major trends in the market. Competition in the market is expected to further intensify with the entry of new drugs in the market during the forecast period. The landscape is vast, with competitors ranging from Arena Pharmaceuticals and Orexigen Therapeutics to big pharmaceutical companies gearing up to make harmless anti-obesity drugs with lesser side effects. According to the report, an increase in the prevalence of obesity is one of the main drivers of the market. The prevalence of obesity is very high worldwide. An increase in the prevalence of obesity offers huge opportunities for drug manufacturing companies to develop and manufacture highly effective drugs. Further, the report states that the high cost of development of drugs is one of the primary challenges faced by the market. Regardless of the numerous benefits, the high cost involved with the development of anti-obesity drugs has direct impact on the pricing of the drug, thereby impeding the acceptability among patients. The Global Anti-obesity Drugs market can be divided into two segments: - Peripherally Acting Anti-obesity Drugs - Centrally Acting Anti-obesity Drugs Key Vendors - Arena Pharmaceuticals - F. Hoffmann-La Roche - GlaxoSmithKline - Orexigen Therapeutics - Vivus Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Types of Obesity - Causes of Obesity - Classification of Obesity - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/pvmmtv/global
OREX: 5.74 (-0.02), GSK: 42.42 (-0.93), ARNA: 3.91 (-0.18)
This Growing Concern Accounts For Nearly 500,000 Cancer Cases Each Year
Sean Williams, The Motley Fool - Motley Fool - Sun Dec 07, 12:51PM CST
Source: WIkimedia Commons. When it comes to diagnosed diseases and disorders few, if any, are scarier than cancer. Based on statistics from the Centers for Disease Control and Prevention, cancer is the second-leading cause of death in the United...
ZFGN: 22.56 (+0.08), OREX: 5.74 (-0.02), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Will Diabetes Drugs Enter The Anti-Obesity Space?
Spencer Osborne - at Seeking Alpha - Sun Dec 07, 5:58AM CST
OREX: 5.74 (-0.02), NVO: 44.48 (-1.14), AZN: 71.80 (-1.80), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Critical Alerts For Apache Corporation, Dreamworks Animation, FireEye, CyberArk Software and Orexigen Therapeutics Released By InvestorsObserver
PR Newswire - Fri Dec 05, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for APA, DWA, FEYE, CYBR and OREX.
OREX: 5.74 (-0.02), FEYE: 29.12 (-0.32), CYBR: 37.98 (+0.13), APA: 56.44 (-0.60), DWA: 21.75 (+0.04)
Why Orexigen Therapeutics (OREX) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 7:52AM CST
Orexigen Therapeutics is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
OREX: 5.74 (-0.02)
Orexigen Therapeutics Up 43.5% Since SmarTrend Uptrend Call (OREX)
Comtex SmarTrend(R) - Wed Dec 03, 9:38AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on October 17th, 2014 at $4.16. In approximately 2 months, Orexigen Therapeutics has returned 43.51% as of today's recent price of $5.97.
OREX: 5.74 (-0.02)
Earnings Estimates Moving Higher for Orexigen (OREX): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 7:51AM CST
Orexigen has been witnessing an upward trend in its current year earnings estimate and its share price has been rising for past 4 weeks
OREX: 5.74 (-0.02)
Why Orexigen Therapeutics, Inc. Stock Rocketed 43% Higher in November
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 03, 7:36AM CST
OREX data by YCharts What: Shares of Orexigen Therapeutics , a biopharmaceutical company focused on developing drugs to treat obesity, put on some serious heft and gained 43% during the month of November, data courtesy of S&P Capital IQ...
OREX: 5.74 (-0.02), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Strong On High Volume: Orexigen Therapeutics (OREX)
at The Street - Tue Dec 02, 9:01AM CST
Trade-Ideas LLC identified Orexigen Therapeutics (OREX) as a strong on high relative volume candidate
OREX: 5.74 (-0.02)
Orexigen Therapeutics Has Returned 39.2% Since SmarTrend Recommendation (OREX)
Comtex SmarTrend(R) - Wed Nov 26, 9:11AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on October 17th, 2014 at $4.16. In approximately 1 month, Orexigen Therapeutics has returned 39.18% as of today's recent price of $5.79.
OREX: 5.74 (-0.02)
Orexigen Therapeutics to Present at the Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 26, 7:30AM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Piper Jaffray Healthcare Conference in New York. The presentation is scheduled for Wednesday, December 3rd at 12:30 p.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
OREX: 5.74 (-0.02)
December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey
at The Street - Wed Nov 26, 5:00AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.
BLUE: 91.28 (+5.16), OREX: 5.74 (-0.02), BCRX: 10.06 (+0.02), ALNY: 100.45 (+0.23), ACHN: 13.28 (-0.11), MRK: 57.72 (-1.62), INCY: 74.65 (-1.27), EPZM: 18.35 (-1.45), AGIO: 119.56 (+0.36), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)
Arena Pharmaceuticals: Belviq Sales Take A Modest Dip With Holiday
Spencer Osborne - at Seeking Alpha - Sat Nov 22, 1:51PM CST
OREX: 5.74 (-0.02), VVUS: 3.00 (-0.01), ARNA: 3.91 (-0.18)
Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl extended release)
PR Newswire - Fri Nov 21, 7:00AM CST
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the Company has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for U.S. Patent Application No. 11/757,773, which covers use of Orexigen's sustained release formulation of naltrexone, which was designed to improve drug tolerability for Contrave® (naltrexone HCl / bupropion HCl extended release), in a method for treating obesity. The patent is expected to expire in March of 2028. Orexigen expects the patent to be listed in the Orange Book maintained by the United States Food and Drug Administration.
OREX: 5.74 (-0.02)
Uptrend Call Working As Orexigen Therapeutics Stock Rises 35.1% (OREX)
Comtex SmarTrend(R) - Tue Nov 18, 4:54PM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on October 17th, 2014 at $4.16. In approximately 1 month, Orexigen Therapeutics has returned 35.10% as of today's recent price of $5.62.
OREX: 5.74 (-0.02)
